View Older Stories View More Recent Stories

Oct 6, 2025 07:30AM Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Oct 3, 2025 04:15PM Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 27, 2025 07:30AM Context Therapeutics to Participate in Upcoming Investor Conferences
Aug 6, 2025 04:11PM Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
Jun 2, 2025 07:30AM Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
May 29, 2025 07:31AM Context Therapeutics (CNTX) Appoint Dr. Karen Chagin as Chief Medical Officer
May 29, 2025 07:30AM Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
May 12, 2025 04:38PM Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2025 04:09PM Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
May 5, 2025 04:06PM Context Therapeutics (CNTX) Announces Chief Medical Officer Transition
May 5, 2025 04:05PM Context Therapeutics Announces Chief Medical Officer Transition
Apr 30, 2025 07:31AM Context Therapeutics (CNTX) Presents Preclinical and Translational Data for CT-95
Apr 30, 2025 07:30AM Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Apr 9, 2025 07:30AM Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Apr 1, 2025 07:30AM Context Therapeutics to Participate in Upcoming Investor Conferences
Mar 26, 2025 04:02PM Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Mar 20, 2025 04:22PM Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Feb 24, 2025 05:05PM Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 19, 2025 07:30AM Context Therapeutics to Participate in Upcoming Investor Conferences
Jan 14, 2025 04:59PM Context Therapeutics (CNTX) Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Jan 14, 2025 04:58PM Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Jan 13, 2025 07:30AM Context Therapeutics (CNTX) Appoints Andy Pasternak as Board Chair
Jan 13, 2025 07:30AM Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Nov 6, 2024 04:06PM Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Oct 23, 2024 07:30AM Context Therapeutics to Participate in Upcoming Investor Conferences in November
Oct 16, 2024 07:30AM Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Sep 23, 2024 07:31AM BioAtla (BCAB) and Context Therapeutics (CNTX) Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362
Sep 23, 2024 07:30AM BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Sep 4, 2024 07:31AM Context Therapeutics (CNTX) Appoints Karen Smith and Luke Walker to its Board
Sep 4, 2024 07:30AM Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
Aug 7, 2024 04:17PM Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Aug 1, 2024 07:31AM Context Therapeutics (CNTX) Appoints Claudio Dansky Ullmann as Chief Medical Officer
Aug 1, 2024 07:30AM Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Jul 10, 2024 07:30AM Context Therapeutics (CNTX) Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 07:30AM Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
May 8, 2024 04:06PM Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 2, 2024 07:32AM Context Therapeutics (CNTX) Announces FDA Clearance of IND Application for a Phase 1 Trial of CTIM-76
May 2, 2024 07:31AM Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Apr 1, 2024 07:30AM Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Mar 21, 2024 07:43AM Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Nov 9, 2023 04:15PM Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
Oct 31, 2023 09:01AM Context Therapeutics (CNTX) Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
Oct 31, 2023 09:00AM Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
Sep 27, 2023 09:00AM Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Aug 9, 2023 04:10PM Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Aug 1, 2023 07:30AM Context Therapeutics to Participate in Two August 2023 Investor Conferences
May 10, 2023 04:39PM Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
Apr 3, 2023 07:30AM Context Therapeutics to Participate in Two April 2023 Investor Conferences
Apr 3, 2023 07:30AM Context Therapeutics to Participate in Two April 2023 Investor Conferences
Mar 22, 2023 05:08PM Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
View More Recent Stories View Older Stories